New treatments of diabetes: the beta-amylin agonists.
Lebovitz
H E
HE
Health Science Center at Brooklyn, Endocrinology & Metabolism/Diabetes, State University of New York, 450 Clarkson Avenue, Brooklyn, NY 11203, USA. hlebovitz1@hotmail.com
D000682:Amyloid / Q000819:agonists* / Q000172:deficiency / Q000494:pharmacology / Q000502:physiology / Q000627:therapeutic use*; D000818:Animals; D003920:Diabetes Mellitus / Q000188:drug therapy* / Q000503:physiopathology; D003922:Diabetes Mellitus, Type 1 / Q000188:drug therapy; D003924:Diabetes Mellitus, Type 2 / Q000188:drug therapy; D004435:Eating / Q000187:drug effects; D005934:Glucagon / Q000378:metabolism; D006801:Humans; D007004:Hypoglycemic Agents / Q000494:pharmacology* / Q000627:therapeutic use*; D007328:Insulin / Q000627:therapeutic use; D058228:Islet Amyloid Polypeptide
D000682:Amyloid; D007004:Hypoglycemic Agents; D007328:Insulin; D058228:Islet Amyloid Polypeptide; D005934:Glucagon; C105254:pramlintide